-- 独立研究机构CFRA向提供了以下研究报告。CFRA分析师的观点总结如下：我们下调了NVR未来12个月的目标价5,519美元（此前为6,100美元），相当于我们2027年每股收益预期380.20美元的14.5倍。我们的估值倍数与过去10年的平均水平一致，我们认为这反映了NVR较低的市场重叠度以及美国消费者因高房价而持观望态度。我们将2026年每股收益预期从405.94美元下调至344.92美元，并将2027年每股收益预期从420.72美元下调至380.20美元。鉴于第一季度业绩未达预期，我们认为2026年的收入预期已有所调整。作为一家规模较大的公司，NVR应该能够继续保持其市场份额，但在市场环境恶化的情况下，这可能会付出高昂的代价。我们预测，到2026年，平均售价将面临压力，而销售、管理及行政费用（SG&A）方面的投资将挤压利润率。虽然这并非我们的基本预期，但在市场环境恶化的情况下，我们预计NVR的债务负担可能会增加。从估值角度来看，该股目前的交易价格较同行溢价30%，而其历史溢价则高达70%。鉴于消费者的不确定性，我们认为目前的溢价是合理的，而非买入良机。
Related Articles
Insider Trading
Lifestance Health Group Insider Sold Shares Worth $492,400, According to a Recent SEC Filing
Robert Bessler, Director, on April 23, 2026, sold 69,899 shares in Lifestance Health Group (LFST) for $492,400. Following the Form 4 filing with the SEC, Bessler has control over a total of 1,485,228 common shares of the company, with 57,619 shares held directly and 1,427,609 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1845257/000119312526182153/xslF345X05/ownership.xml
$LFST
Australia
Celestica Q1 Adjusted Earnings, Revenue Rise; Q2 Guidance Set
Celestica (CLS) reported Q1 adjusted earnings late Monday of $2.16 per diluted share, up from $1.20 a year earlier.Analysts polled by FactSet expected $2.07.Revenue for the three months ended March 31 was $4.05 billion, up from $2.65 billion a year earlier.Analysts surveyed by FactSet expected $4.04 billion.For Q2, the company expects adjusted EPS of $2.14 to $2.34 on revenue of $4.15 billion to $4.45 billion. Analysts expect EPS of $2.13 on revenue of $4.17 billion.The company now expects 2026 adjusted EPS of $10.15 on revenue of $19 billion, revised from $8.75 and $17 billion, respectively, expected earlier. Analysts expect EPS of $8.93 on revenue of $17.34 billion.
$CLS
Research
Research Alert: CFRA Keeps Buy Opinion On Shares Of Ameriprise Financial, Inc.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We keep our 12-month target price of $550, valuing AMP shares at 12.5x our 2026 adjusted EPS estimate of $43.84 (raised by $1.34) and at 11.7x our 2027 EPS estimate of $46.90 (raised by $0.70). This compares to the three-year average forward multiple of 12x and peer average of 15.5x. AMP posted Q1 2026 adjusted operating EPS of $11.26 vs. $9.50, a 19% rise that topped our $10.12 estimate and $10.21 consensus view. Revenue growth of 11% exceeded our forecast and our 6%-10% growth forecast for 2026, while pretax adjusted operating margins expanded 130 bps to 28% on revenue gains and cost containment efforts. We now see revenue growth of 7% to 12% in 2026 and 2027. AMP also continued its substantial capital return program, returning $936M to shareholders in Q1 (70% of adjusted operating earnings) and $3.4B in 2025 (88% of earnings). Currently trading at 10.9x our 2026 EPS estimate, and with some decent revenue and earnings momentum, we view the shares as undervalued versus peer and historical averages.
$AMP